Addressing Post Cessation Weight Gain
Primary Purpose
Obesity, Smoking Cessation
Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
lorcaserin
Varenicline
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Obesity
Eligibility Criteria
Inclusion Criteria:
Subjects will be considered for inclusion if they meet all of the following
- ≥18 years and ≤65 years of age;
- smoked ≥10 cigarettes/day for the past 6 months;
- Body Mass Index of 27-39.9 kg/m2;
- motivated to stop smoking;
- weight concerned as shown with the Weight Concern Scale;
- able to participate fully in all aspects of the study;
- understand and signed the study informed consent.
- Subject is in good health as determined by the clinical investigators.
Exclusion Criteria:
Subjects will be ineligible for participation if they have any of the following:
- current nonspecific suicidal thoughts or a lifetime history of a suicidal attempt (defined by the Columbia-Suicide Severity Rating Scale as a "potentially self-injurious act committed with at least some wish to die, as a result of act.");
- current moderate or severe depression as assessed by a score of ≥16 on the Center for Epidemiology Studies-Depression;
- a lifetime history of psychosis, bipolar disorder or schizophrenia;
- use of anti-psychotic medication within the past 30 days;
- use of weight-loss medications within the past 30 days or current participation in a program specifically designed to help with weight loss;
- weight fluctuations of 20 pounds or more in the past 6 months (self-report);
- use of any treatments for tobacco dependence within the past 30 days;
- use of an investigational drug within the past 30 days;
- recent history (past 3 months) of abuse of or dependence on a substance other than tobacco. Including: heavy alcohol consumption (If male, drinking > 4 alcoholic beverages per day for past month and if female, drinking > 3 alcoholic beverages per day for past month); use of cocaine, heroin, club drugs (i.e., methylenedioxymethamphetamine(MDMA)/"ecstasy"), methamphetamine, or hallucinogens (e.g., LSD) at any time during the past 3 months; and use of marijuana on a weekly basis for the past 3 months
- current use of triptans, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRI), selective serotonin-norepinephrine re-uptake inhibitors (SNRI), dextromethorphan, tricyclic antidepressants (TCA), bupropion, lithium, tramadol, tryptophan, and St. John's Wort, or any other medication known to involve the serotonergic neurotransmitter system (see human subjects section);
- uncontrolled hypertension (systolic >160 mm Hg and/or diastolic >100 mm Hg) documented on 2 separate occasions;
- current use of medications known to interact with varenicline or lorcaserin. These can include benzodiazepines, narcotics, anti-epileptics;
- another household member or relative participating in the study;
- known diabetes;
- a known allergy to varenicline or lorcaserin.
- Women who are pregnant or lactating, or who are of childbearing potential and are likely to become pregnant during the medication phase but are not willing to use a reliable form of contraception, will also be excluded. Reliable forms of contraception include oral contraception, diaphragm or condom (with spermicide), injections, intrauterine device, surgical sterilization, and abstinence.
- Has an unstable medical condition as determined by the physician investigator
- Subject describes having a medical history of: a) unstable angina; b) myocardial infarction within the past 3 months; c) coronary angioplasty or d) an untreated cardiac dysrhythmia.
- Subject currently has cancer [excluding non-melanoma skin cancer] not in remission
- Known history of seizures
Sites / Locations
- Mayo Clinic in Rochester
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Varenicline plus placebo
Varenicline plus lorcaserin
Arm Description
Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)
Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)
Outcomes
Primary Outcome Measures
Post Cessation Weight Gain (kg)
weight (kg) change from baseline to week 24 among subjects who meet criteria for prolonged smoking abstinence at week 24
Secondary Outcome Measures
BMI
BMI change from baseline to week 24
Smoking Abstinence
Lorcaserin combined with open label varenicline will be evaluated for improved smoking abstinence compared to placebo
Waist Circumference
Waist Circumference change from baseline to week 24
Fat Mass
Body Fat difference from baseline to week 24.
Full Information
NCT ID
NCT02412631
First Posted
March 12, 2015
Last Updated
May 17, 2021
Sponsor
Mayo Clinic
Collaborators
National Institute on Drug Abuse (NIDA)
1. Study Identification
Unique Protocol Identification Number
NCT02412631
Brief Title
Addressing Post Cessation Weight Gain
Official Title
Varenicline and Lorcaserin for Smoking Cessation and Weight Gain Prevention
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Terminated
Why Stopped
Lorcaserin removed from market
Study Start Date
June 15, 2016 (Actual)
Primary Completion Date
April 17, 2020 (Actual)
Study Completion Date
April 17, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic
Collaborators
National Institute on Drug Abuse (NIDA)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Some individuals smoke with the perception that smoking helps control body weight. Smokers gain an average of as much as 10 pounds in the months following smoking abstinence, with heavier and more-dependent smokers gaining more weight. T The Mayo Clinic Nicotine Research Program will randomize 100 nondiabetic, overweight or obese adult smokers to active lorcaserin or placebo for 24 weeks; all of the subjects will receive open-label varenicline for 12 weeks. The purpose of this study is to assess the efficacy of a 24-week course of lorcaserin for decreasing weight gain after stopping smoking.
Detailed Description
This will be a randomized, placebo-controlled, parallel-group clinical trial. Nondiabetic, overweight and obese adult smokers will be randomized to one of three arms:
lorcaserin for 24 weeks in combination with varenicline for 12 weeks;
placebo for 24 weeks in combination with varenicline for 12 weeks;
We will assess the following:
changes in weight and Weight Concern
7-day point-prevalence smoking abstinence weekly through week 24 and prolonged smoking abstinence at 24 and 52 weeks. Subjects will have a target quit date 8 days after starting medication.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Smoking Cessation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
84 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Varenicline plus placebo
Arm Type
Placebo Comparator
Arm Description
Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)
Arm Title
Varenicline plus lorcaserin
Arm Type
Experimental
Arm Description
Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)
Intervention Type
Drug
Intervention Name(s)
lorcaserin
Other Intervention Name(s)
Belviq
Intervention Description
lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
Intervention Type
Drug
Intervention Name(s)
Varenicline
Other Intervention Name(s)
Chantix
Intervention Description
Chantix is an FDA approved medication for smoking cessation
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo for lorcaserin
Primary Outcome Measure Information:
Title
Post Cessation Weight Gain (kg)
Description
weight (kg) change from baseline to week 24 among subjects who meet criteria for prolonged smoking abstinence at week 24
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
BMI
Description
BMI change from baseline to week 24
Time Frame
24 weeks
Title
Smoking Abstinence
Description
Lorcaserin combined with open label varenicline will be evaluated for improved smoking abstinence compared to placebo
Time Frame
24 weeks
Title
Waist Circumference
Description
Waist Circumference change from baseline to week 24
Time Frame
24 weeks
Title
Fat Mass
Description
Body Fat difference from baseline to week 24.
Time Frame
24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Subjects will be considered for inclusion if they meet all of the following
≥18 years and ≤65 years of age;
smoked ≥10 cigarettes/day for the past 6 months;
Body Mass Index of 27-39.9 kg/m2;
motivated to stop smoking;
weight concerned as shown with the Weight Concern Scale;
able to participate fully in all aspects of the study;
understand and signed the study informed consent.
Subject is in good health as determined by the clinical investigators.
Exclusion Criteria:
Subjects will be ineligible for participation if they have any of the following:
current nonspecific suicidal thoughts or a lifetime history of a suicidal attempt (defined by the Columbia-Suicide Severity Rating Scale as a "potentially self-injurious act committed with at least some wish to die, as a result of act.");
current moderate or severe depression as assessed by a score of ≥16 on the Center for Epidemiology Studies-Depression;
a lifetime history of psychosis, bipolar disorder or schizophrenia;
use of anti-psychotic medication within the past 30 days;
use of weight-loss medications within the past 30 days or current participation in a program specifically designed to help with weight loss;
weight fluctuations of 20 pounds or more in the past 6 months (self-report);
use of any treatments for tobacco dependence within the past 30 days;
use of an investigational drug within the past 30 days;
recent history (past 3 months) of abuse of or dependence on a substance other than tobacco. Including: heavy alcohol consumption (If male, drinking > 4 alcoholic beverages per day for past month and if female, drinking > 3 alcoholic beverages per day for past month); use of cocaine, heroin, club drugs (i.e., methylenedioxymethamphetamine(MDMA)/"ecstasy"), methamphetamine, or hallucinogens (e.g., LSD) at any time during the past 3 months; and use of marijuana on a weekly basis for the past 3 months
current use of triptans, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRI), selective serotonin-norepinephrine re-uptake inhibitors (SNRI), dextromethorphan, tricyclic antidepressants (TCA), bupropion, lithium, tramadol, tryptophan, and St. John's Wort, or any other medication known to involve the serotonergic neurotransmitter system (see human subjects section);
uncontrolled hypertension (systolic >160 mm Hg and/or diastolic >100 mm Hg) documented on 2 separate occasions;
current use of medications known to interact with varenicline or lorcaserin. These can include benzodiazepines, narcotics, anti-epileptics;
another household member or relative participating in the study;
known diabetes;
a known allergy to varenicline or lorcaserin.
Women who are pregnant or lactating, or who are of childbearing potential and are likely to become pregnant during the medication phase but are not willing to use a reliable form of contraception, will also be excluded. Reliable forms of contraception include oral contraception, diaphragm or condom (with spermicide), injections, intrauterine device, surgical sterilization, and abstinence.
Has an unstable medical condition as determined by the physician investigator
Subject describes having a medical history of: a) unstable angina; b) myocardial infarction within the past 3 months; c) coronary angioplasty or d) an untreated cardiac dysrhythmia.
Subject currently has cancer [excluding non-melanoma skin cancer] not in remission
Known history of seizures
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ryan T Hurt, MD, PhD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
36160639
Citation
Hurt RT, Croghan IT, Schroeder DR, Choi DS, Fischer K, Fokken S, Ebbert JO. Varenicline and Lorcaserin for Smoking Cessation and Weight Gain Prevention: A Randomized Clinical Trial. Mayo Clin Proc Innov Qual Outcomes. 2022 Sep 21;6(5):465-474. doi: 10.1016/j.mayocpiqo.2022.01.004. eCollection 2022 Oct.
Results Reference
derived
Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials
Learn more about this trial
Addressing Post Cessation Weight Gain
We'll reach out to this number within 24 hrs